<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483961</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-CV-317-001</org_study_id>
    <nct_id>NCT03483961</nct_id>
  </id_info>
  <brief_title>Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults</brief_title>
  <official_title>A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of&#xD;
      various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To assess the immune response to the vaccine&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the kinetics of the immune response to different doses/formulations/schedules To&#xD;
      assess the persistence of immune responses to different doses/formulations/schedules To&#xD;
      assess the effect of a booster dose of the vaccine&#xD;
&#xD;
      Safety Objective:&#xD;
&#xD;
      To assess local and systemic reactions to the vaccine and to describe the safety profile of&#xD;
      the vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will explore 8 formulation/schedule combinations of CHIKV VLP vaccine with or&#xD;
      without Alhydrogel adjuvant, and will also explore different dose schedules of Day 1 and 15&#xD;
      or Day 1 and 29 or Day 29 only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Actual">September 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.</measure>
    <time_frame>Day 57 (from Day 1 vaccination), 28 days after the last injection.</time_frame>
    <description>To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</measure>
    <time_frame>At Days 8, 15, 22, 29, 36, and 57.</time_frame>
    <description>To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</measure>
    <time_frame>At Days 182, 365, 547, and 760.</time_frame>
    <description>To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.</measure>
    <time_frame>Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.</time_frame>
    <description>To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.</measure>
    <time_frame>Day 57 (from Day 1 vaccination), 28 days after the last injection.</time_frame>
    <description>Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">445</enrollment>
  <condition>Chikungunya Virus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: 20 mcg/unadjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 6 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 10 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 20mcg/adjuvanted (Day 1 &amp; 29);40mcg/adjuvant (Day 547)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: 6 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: 10 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: 20 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8: 40 mcg/adjuvanted (Day 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9: 20 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10: 40 mcg/adjuvanted (Day 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/unadjuvanted</intervention_name>
    <description>Vaccine consists of virus-like particles of chikungunya virus antigens</description>
    <arm_group_label>Group 1: 20 mcg/unadjuvanted (Day 1 &amp; 29)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/adjuvanted</intervention_name>
    <description>Adjuvanted formulation includes Alhydrogel</description>
    <arm_group_label>Group 10: 40 mcg/adjuvanted (Day 1)</arm_group_label>
    <arm_group_label>Group 2: 6 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_label>Group 3: 10 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_label>Group 4: 20mcg/adjuvanted (Day 1 &amp; 29);40mcg/adjuvant (Day 547)</arm_group_label>
    <arm_group_label>Group 5: 6 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 6: 10 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 7: 20 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 8: 40 mcg/adjuvanted (Day 29)</arm_group_label>
    <arm_group_label>Group 9: 20 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is vaccine diluent alone</description>
    <arm_group_label>Group 1: 20 mcg/unadjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_label>Group 2: 6 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_label>Group 3: 10 mcg/adjuvanted (Day 1 &amp; 29)</arm_group_label>
    <arm_group_label>Group 4: 20mcg/adjuvanted (Day 1 &amp; 29);40mcg/adjuvant (Day 547)</arm_group_label>
    <arm_group_label>Group 5: 6 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 6: 10 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 7: 20 mcg/adjuvanted (Day 15 &amp; 29)</arm_group_label>
    <arm_group_label>Group 8: 40 mcg/adjuvanted (Day 29)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Age 18 to 45 years old (inclusive)&#xD;
&#xD;
          3. Using an acceptable method of contraception (if female of childbearing potential).&#xD;
&#xD;
          4. Able and willing to provide informed consent for study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current acute febrile illness.&#xD;
&#xD;
          2. Clinically significant cardiac, respiratory, or rheumatologic disease, in the opinion&#xD;
             of the Investigator.&#xD;
&#xD;
          3. Pregnant or breast-feeding.&#xD;
&#xD;
          4. Laboratory evidence of infection with Hepatitis B/C or HIV.&#xD;
&#xD;
          5. History of chikungunya virus infection.&#xD;
&#xD;
          6. Travel to a World Health Organization-designated chikungunya-endemic region within 30&#xD;
             days prior to Day 1.&#xD;
&#xD;
          7. History of allergic reaction to any component of CHIKV-VLP vaccine, Diluent, or&#xD;
             Alhydrogel®.&#xD;
&#xD;
          8. Inability to discontinue systemic immunomodulatory or immunosuppressive medications 30&#xD;
             days prior to Day 1.&#xD;
&#xD;
          9. Received or plans to receive any licensed vaccine from 30 days prior to Day 1 through&#xD;
             Day 57.&#xD;
&#xD;
         10. Received or plans to receive an investigational agent from 30 days prior to Day 1&#xD;
             through the duration of study participation.&#xD;
&#xD;
         11. Any other condition that, in the opinion of the Investigator, creates an unacceptable&#xD;
             risk to the subject.&#xD;
&#xD;
         12. Any other condition that, in the opinion of the Investigator, may interfere with the&#xD;
             conduct of the study or the validity of the data.&#xD;
&#xD;
         13. Any other condition that, in the opinion of the Investigator, creates an unacceptable&#xD;
             safety risk for apheresis (Group 9 &amp; 10 only).&#xD;
&#xD;
         14. Restricted venous access that would prevent the collection of PBMCs, plasma, and&#xD;
             lymphocytes necessary for participation (Group 9 &amp; 10 only).&#xD;
&#xD;
         15. Weight &lt; 110 pounds (Group 9 &amp; 10 only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <results_first_submitted>September 14, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Protocol Cover Page</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Protocol Cover Page</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Cover Page</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan Cover Page</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Informed Consent Form Cover page</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/ICF_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Informed Consent Form Cover page</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03483961/ICF_005.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 3 U.S. sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P3">
          <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P4">
          <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P5">
          <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P6">
          <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P7">
          <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P8">
          <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
          <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="P9">
          <title>Group 9: 20 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
        <group group_id="P10">
          <title>Group 10: 40 mcg/Adjuvant (Day 1)</title>
          <description>40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="52"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed / Safety</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="50">One subject was randomized to Group 3 but treated in Group 4 due to a dispensing error.</participants>
                <participants group_id="P4" count="51">One subject was randomized to Group 3 but treated in Group 4 due to a dispensing error.</participants>
                <participants group_id="P5" count="53">One subject did not receive PXVX0317 but is in the Exposed / Safety population because of receipt of placebo.</participants>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="51">One subject did not receive PXVX0317 but is in the Exposed / Safety population because of receipt of placebo.</participants>
                <participants group_id="P8" count="52">Two subjects did not receive PXVX0317 but are in the Exposed / Safety population because of receipt of placebo.</participants>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Immunogenicity-evaluable</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="48"/>
                <participants group_id="P7" count="47"/>
                <participants group_id="P8" count="50"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="46"/>
                <participants group_id="P8" count="39"/>
                <participants group_id="P9" count="18"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B4">
          <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B5">
          <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B6">
          <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B7">
          <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B8">
          <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
          <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="B9">
          <title>Group 9: 20 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
        <group group_id="B10">
          <title>Group 10: 40 mcg/Adjuvant (Day 1)</title>
          <description>40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="51"/>
            <count group_id="B8" value="52"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="445"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="440"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="8.22"/>
                    <measurement group_id="B2" value="31.2" spread="8.26"/>
                    <measurement group_id="B3" value="31.2" spread="7.64"/>
                    <measurement group_id="B4" value="33.7" spread="7.53"/>
                    <measurement group_id="B5" value="30.6" spread="7.72"/>
                    <measurement group_id="B6" value="32.9" spread="7.53"/>
                    <measurement group_id="B7" value="32.4" spread="7.78"/>
                    <measurement group_id="B8" value="31.6" spread="7.82"/>
                    <measurement group_id="B9" value="27.1" spread="7.58"/>
                    <measurement group_id="B10" value="29.6" spread="7.65"/>
                    <measurement group_id="B11" value="31.5" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="49"/>
                    <measurement group_id="B8" value="48"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="410"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="52"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Day 1 predose (baseline) geometric mean anti-chikungunya luciferase neutralizing antibody titer.</title>
          <description>Day 1 predose (baseline) geometric mean anti-chikungunya luciferase neutralizing antibody titer. Values below the lower limit of quantitation of 15 were imputed as half the lower limit of quantitation or 7.5.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="48"/>
                    <count group_id="B6" value="48"/>
                    <count group_id="B7" value="47"/>
                    <count group_id="B8" value="50"/>
                    <count group_id="B9" value="20"/>
                    <count group_id="B10" value="10"/>
                    <count group_id="B11" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B2" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B3" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B4" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B5" value="7.8" lower_limit="7.5" upper_limit="50.3"/>
                    <measurement group_id="B6" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B7" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B8" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="B9" value="8.6" lower_limit="7.5" upper_limit="117.1"/>
                    <measurement group_id="B10" value="9.0" lower_limit="7.5" upper_limit="46.1"/>
                    <measurement group_id="B11" value="7.6" lower_limit="7.5" upper_limit="117.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.</title>
        <description>To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.</description>
        <time_frame>Day 57 (from Day 1 vaccination), 28 days after the last injection.</time_frame>
        <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
            <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
            <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O5">
            <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O6">
            <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O7">
            <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O8">
            <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
            <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.</title>
          <description>To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2057.0" lower_limit="1584.8" upper_limit="2670.0"/>
                    <measurement group_id="O2" value="1116.2" lower_limit="852.5" upper_limit="1461.4"/>
                    <measurement group_id="O3" value="1465.3" lower_limit="1119.1" upper_limit="1918.4"/>
                    <measurement group_id="O4" value="2023.8" lower_limit="1550.5" upper_limit="2641.7"/>
                    <measurement group_id="O5" value="920.1" lower_limit="710.9" upper_limit="1190.9"/>
                    <measurement group_id="O6" value="1206.9" lower_limit="932.4" upper_limit="1562.2"/>
                    <measurement group_id="O7" value="1562.8" lower_limit="1204.1" upper_limit="2028.3"/>
                    <measurement group_id="O8" value="1712.5" lower_limit="1330.0" upper_limit="2205.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 2 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0761</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 3 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9317</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 4 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 5 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 6 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1437</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 7 vs. Group 1.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Groups 2-8 are compared to Group 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3216</p_value>
            <p_value_desc>All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 8 vs. Group 1.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</title>
        <description>To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.</description>
        <time_frame>At Days 8, 15, 22, 29, 36, and 57.</time_frame>
        <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
            <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
            <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O5">
            <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O6">
            <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O7">
            <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O8">
            <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
            <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
        </group_list>
        <measure>
          <title>Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</title>
          <description>To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="53.2" upper_limit="93.7"/>
                    <measurement group_id="O2" value="34.3" lower_limit="25.6" upper_limit="46.1"/>
                    <measurement group_id="O3" value="72.6" lower_limit="54.2" upper_limit="97.2"/>
                    <measurement group_id="O4" value="117.6" lower_limit="87.8" upper_limit="157.4"/>
                    <measurement group_id="O5" value="8.4" lower_limit="6.3" upper_limit="11.1"/>
                    <measurement group_id="O6" value="7.5" lower_limit="5.7" upper_limit="10.0"/>
                    <measurement group_id="O7" value="7.5" lower_limit="5.7" upper_limit="10.0"/>
                    <measurement group_id="O8" value="7.5" lower_limit="5.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.3" lower_limit="323.6" upper_limit="543.4"/>
                    <measurement group_id="O2" value="189.4" lower_limit="144.9" upper_limit="247.6"/>
                    <measurement group_id="O3" value="530.2" lower_limit="405.6" upper_limit="693.0"/>
                    <measurement group_id="O4" value="912.7" lower_limit="700.4" upper_limit="1189.5"/>
                    <measurement group_id="O5" value="7.7" lower_limit="6.0" upper_limit="10.0"/>
                    <measurement group_id="O6" value="7.5" lower_limit="5.8" upper_limit="9.7"/>
                    <measurement group_id="O7" value="7.7" lower_limit="5.9" upper_limit="9.9"/>
                    <measurement group_id="O8" value="7.5" lower_limit="5.8" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691.5" lower_limit="499.2" upper_limit="957.9"/>
                    <measurement group_id="O2" value="351.3" lower_limit="250.9" upper_limit="492.0"/>
                    <measurement group_id="O3" value="1400.2" lower_limit="999.9" upper_limit="1960.8"/>
                    <measurement group_id="O4" value="2198.1" lower_limit="1575.6" upper_limit="3066.5"/>
                    <measurement group_id="O5" value="46.4" lower_limit="33.6" upper_limit="64.1"/>
                    <measurement group_id="O6" value="63.1" lower_limit="45.7" upper_limit="87.1"/>
                    <measurement group_id="O7" value="119.0" lower_limit="85.9" upper_limit="164.9"/>
                    <measurement group_id="O8" value="7.5" lower_limit="5.5" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.2" lower_limit="305.4" upper_limit="570.0"/>
                    <measurement group_id="O2" value="277.3" lower_limit="200.9" upper_limit="382.8"/>
                    <measurement group_id="O3" value="890.5" lower_limit="645.1" upper_limit="1229.2"/>
                    <measurement group_id="O4" value="1238.1" lower_limit="900.2" upper_limit="1702.9"/>
                    <measurement group_id="O5" value="258.0" lower_limit="189.5" upper_limit="351.3"/>
                    <measurement group_id="O6" value="328.8" lower_limit="241.5" upper_limit="447.6"/>
                    <measurement group_id="O7" value="886.2" lower_limit="648.7" upper_limit="1210.5"/>
                    <measurement group_id="O8" value="8.2" lower_limit="6.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="46"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3442.8" lower_limit="2533.9" upper_limit="4677.8"/>
                    <measurement group_id="O2" value="1675.8" lower_limit="1220.9" upper_limit="2300.2"/>
                    <measurement group_id="O3" value="2772.4" lower_limit="2019.8" upper_limit="3805.4"/>
                    <measurement group_id="O4" value="3435.0" lower_limit="2511.4" upper_limit="4698.1"/>
                    <measurement group_id="O5" value="1327.7" lower_limit="980.4" upper_limit="1797.9"/>
                    <measurement group_id="O6" value="2155.4" lower_limit="1591.6" upper_limit="2919.0"/>
                    <measurement group_id="O7" value="3609.0" lower_limit="2647.7" upper_limit="4919.3"/>
                    <measurement group_id="O8" value="157.9" lower_limit="117.3" upper_limit="212.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2057.0" lower_limit="1584.8" upper_limit="2670.0"/>
                    <measurement group_id="O2" value="1116.2" lower_limit="852.5" upper_limit="1461.4"/>
                    <measurement group_id="O3" value="1465.3" lower_limit="1119.1" upper_limit="1918.4"/>
                    <measurement group_id="O4" value="2023.8" lower_limit="1550.5" upper_limit="2641.7"/>
                    <measurement group_id="O5" value="920.1" lower_limit="710.9" upper_limit="1190.9"/>
                    <measurement group_id="O6" value="1206.9" lower_limit="932.4" upper_limit="1562.2"/>
                    <measurement group_id="O7" value="1562.8" lower_limit="1204.1" upper_limit="2028.3"/>
                    <measurement group_id="O8" value="1712.5" lower_limit="1330.0" upper_limit="2205.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</title>
        <description>To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.</description>
        <time_frame>At Days 182, 365, 547, and 760.</time_frame>
        <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
            <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
            <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O5">
            <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O6">
            <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O7">
            <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O8">
            <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
            <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.</title>
          <description>To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 182</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.1" lower_limit="258.1" upper_limit="461.3"/>
                    <measurement group_id="O2" value="209.0" lower_limit="153.1" upper_limit="285.2"/>
                    <measurement group_id="O3" value="358.4" lower_limit="261.6" upper_limit="491.2"/>
                    <measurement group_id="O4" value="486.6" lower_limit="360.5" upper_limit="656.9"/>
                    <measurement group_id="O5" value="253.4" lower_limit="188.4" upper_limit="340.9"/>
                    <measurement group_id="O6" value="303" lower_limit="226.7" upper_limit="405.0"/>
                    <measurement group_id="O7" value="388.1" lower_limit="291.3" upper_limit="517.1"/>
                    <measurement group_id="O8" value="505.7" lower_limit="380.7" upper_limit="671.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="43"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.4" lower_limit="176.8" upper_limit="334.9"/>
                    <measurement group_id="O2" value="137.5" lower_limit="98.3" upper_limit="192.3"/>
                    <measurement group_id="O3" value="226.7" lower_limit="160.6" upper_limit="320.0"/>
                    <measurement group_id="O4" value="336.6" lower_limit="244.6" upper_limit="463.2"/>
                    <measurement group_id="O5" value="195.2" lower_limit="141.3" upper_limit="269.6"/>
                    <measurement group_id="O6" value="246.9" lower_limit="180.1" upper_limit="338.4"/>
                    <measurement group_id="O7" value="302.0" lower_limit="220.3" upper_limit="414.0"/>
                    <measurement group_id="O8" value="491.7" lower_limit="362.5" upper_limit="667.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 547</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.2" lower_limit="126.2" upper_limit="226.8"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O4" value="215.7" lower_limit="160.9" upper_limit="289.1"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O8" value="297.9" lower_limit="221.4" upper_limit="400.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 760</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.8" lower_limit="122.4" upper_limit="235.5"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O4" value="5365.1" lower_limit="3853.2" upper_limit="7470.1"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Follow-up to Day 365 in this group.</measurement>
                    <measurement group_id="O8" value="279.7" lower_limit="200.1" upper_limit="391.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.</title>
        <description>To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.</description>
        <time_frame>Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.</time_frame>
        <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
            <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
        </group_list>
        <measure>
          <title>Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.</title>
          <description>To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 547 (pre-boost)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.6" lower_limit="166.7" upper_limit="299.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 575 (post-boost)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12325.8" lower_limit="8951.4" upper_limit="16972.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 760 (post-boost)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5874.2" lower_limit="4269.4" upper_limit="8082.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.</title>
        <description>Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.</description>
        <time_frame>Day 57 (from Day 1 vaccination), 28 days after the last injection.</time_frame>
        <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
            <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
            <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
            <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O5">
            <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O6">
            <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O7">
            <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
            <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
          <group group_id="O8">
            <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
            <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.</title>
          <description>Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.</description>
          <population>Immunogenicity-evaluable: Exposed participants as treated per protocol (no major protocol deviation or exclusion reason prior to unblinding, all doses received, no prohibited medication, and evaluable serum samples within required time frames).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Titer at or above 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer at or above 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer at or above 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer at or above 640</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="41"/>
                    <measurement group_id="O8" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer at or above 4-fold rise over baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited adverse events were monitored through Day 760 (Groups 1, 4, and 8), Day 365 (Groups 2, 3, 5, 6, and 7), Day 182 (Group 9), and Day 29 (Group 10), but only unsolicited adverse events occurring through Day 57 (end of treatment and observation period, 28 days after last dose for Groups 1-8) are reported.</time_frame>
      <desc>One subject was randomized to Group 3 but treated in Group 4 due to a dispensing error. This participant was counted in Group 3 in the Participant Flow Number Started but was counted in Group 4 for the safety population for all safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 20 mcg/Unadjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)&#xD;
CHIKV VLP/unadjuvanted: Vaccine consists of virus-like particles of chikungunya virus antigens&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 6 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E3">
          <title>Group 3: 10 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E4">
          <title>Group 4: 20mcg/Adjuvant(Day 1 &amp; 29);40mcg/Adjuvant (Day 547)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E5">
          <title>Group 5: 6 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E6">
          <title>Group 6: 10 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E7">
          <title>Group 7: 20 mcg/Adjuvant (Day 15 &amp; 29)</title>
          <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E8">
          <title>Group 8: 40 mcg/Adjuvant (Day 29)</title>
          <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel&#xD;
Placebo: Placebo is vaccine diluent alone</description>
        </group>
        <group group_id="E9">
          <title>Group 9: 20 mcg/Adjuvant (Day 1 &amp; 29)</title>
          <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
        <group group_id="E10">
          <title>Group 10: 40 mcg/Adjuvant (Day 1)</title>
          <description>40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.&#xD;
CHIKV VLP/adjuvanted: Adjuvanted formulation includes Alhydrogel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Induced abortion haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laryngeal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea, solicited</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pain, solicited</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E2" events="41" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E3" events="35" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E4" events="63" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E5" events="25" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E6" events="27" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E7" events="30" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E8" events="32" subjects_affected="26" subjects_at_risk="52"/>
                <counts group_id="E9" events="16" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue, solicited</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E4" events="27" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E7" events="17" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E8" events="15" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malaise, solicited</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E7" events="13" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E8" events="11" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills, solicited</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia, solicited</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia, solicited</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="18" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E4" events="35" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E6" events="18" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E7" events="19" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia, solicited</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" events="8" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache, solicited</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" events="23" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E4" events="31" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E6" events="17" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" events="19" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E8" events="26" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI may publish or release study data after the earlier of (a) the date of publication of a multi-center publication coordinated by Sponsor on the study data, or (b) the date of submission of the study data by Sponsor to regulatory authorities for regulatory approval; provided that PI furnishes Sponsor with a copy of any proposed publication or release at least ninety days in advance of the proposed submission or presentation date for review. PI must acknowledge Sponsor on any publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharmila Rajendran</name_or_title>
      <organization>Emergent BioSolutions</organization>
      <phone>650-486-0244</phone>
      <email>rajendras@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

